Biomaterials Executive, Arthur J. Coury, PhD, Joins InVivo Therapeutics’ Business Advisory Board
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 10, 2012--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Arthur J. Coury, PhD, has joined the company as an advisor to the CEO.
Dr. Coury’s focus on polymeric biomaterials for medical products such as implantable devices, hydrogel-based devices and drug delivery systems will bring critical expertise to InVivo as the company awaits approval to begin human studies. Dr. Coury’s experience and leadership has led to FDA approval of multiple hydrogel products, and has been drawn from his positions as Senior Research Chemist at General Mills, Inc.; Director, Polymer Technology and Research Fellow at Medtronic, Inc.; Vice President, Research and Chief Scientific Officer at Focal, Inc.; Vice President, Biomaterials Research at Genzyme Corporation; and most recently, his work as a consultant.
Dr. Coury holds over fifty distinct patents and has published and presented widely in the field of biomaterials. In addition, Dr. Coury’s professional service to his field includes serving as Chair of the Minnesota Section of the American Chemical Society; as President for the Society for Biomaterials, USA; and as President for the American Institute for Medical and Biological Engineering (AIMBE).
His recent recognitions have included the receipt of the 2007 Innovation and Technology Development Award of the Society for Biomaterials, being named as one of “100 Notable People in the Medical Device Industry” by MD&DI magazine, 2008, induction into the National Academy of Engineering, USA, 2009, recognition on the University of Delaware alumni “Wall of Fame,” 2010, “The Man, the Myth, the Materials,” a symposium in honor of Dr. Coury’s 70 th birthday, 2010, induction as an American Chemical Society Fellow, 2011, and as recipient of the Society for Biomaterials Founders’ Award, 2012 and of the AIMBE Pierre Galletti award for 2012.
Said InVivo Therapeutics CEO Frank Reynolds, “Biomaterials engineers with strong track records of executive leadership and success are a rarity, so adding Art Coury to our team is a real coup for InVivo. We look forward to having Art contribute right away by helping us scale up our company.” Dr. Coury holds a Ph.D. in organic chemistry and an M.B.A. from the University of Minnesota, and a B.S. in Chemistry from the University of Delaware.
About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.CONTACT: InVivo Therapeutics Holdings Corp.
Lauren Mitarotondo, (617) 863-5510 email@example.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL OTHER HEALTH RESEARCH SCIENCE SOURCE: InVivo Therapeutics Holdings Corp. Copyright Business Wire 2012 PUB: 09/10/2012 04:35 PM/DISC: 09/10/2012 04:35 PM http://www.businesswire.com/news/home/20120910006838/